Hemodynamic response to intentionally altered flow continuity of dobutamine and dopamine by an infusion pump in infants

被引:0
|
作者
Stowe, CD
Storgion, SA
Lee, KR
Phelps, SJ
机构
[1] UNIV TENNESSEE,CTR HLTH SCI,DEPT CLIN PHARM,MEMPHIS,TN 38163
[2] UNIV TENNESSEE,DEPT PEDIAT,MEMPHIS,TN 38163
[3] UNIV ARKANSAS MED SCI HOSP,DEPT PHARM PRACTICE,LITTLE ROCK,AR
来源
PHARMACOTHERAPY | 1996年 / 16卷 / 06期
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objective. To evaluate the effect of an intentional alteration in infusion pump flow continuity on the hemodynamic stability of infants receiving either dobutamine or dopamine. Design. Prospective, open-label study. Setting. A university-affiliated children's hospital. Patients. en hemodynamically stable infants (age 2 wks-10 mo) in intensive care receiving dobutamine (5) or dopamine (5). Three patients received both agents and were studied at independent times. Interventions. Dobutamine and dopamine were administered using the Flo-Gard VP pump that delivers an intentional alteration of flow continuity (rate pulse). Heart rate and mean arterial pressure (MAP) were recorded every second. Analysis was based on the measurements obtained from the first 5 minutes on the study pump and the 2 minutes before and after the rate pulse. Measurements and Main Results. Although hemodynamic changes in pre- and post-rate pulses were statistically significant (p<0.05) in some individuals, only one infant had a greater that 10% change in MAP 2 minutes after the rate pulse. Alterations in hemodynamics were not consistent among or within patients. Conclusion. In infants requiring dobutamine or dopamine, no clinically significant pharmacodynamic effects were associated with alteration in continuity of drug delivery caused by the single positive rate pulse. Therefore, we conclude there is no contraindication to the use of this infusion pump in hemodynamically stable infants receiving these drugs.
引用
收藏
页码:1018 / 1023
页数:6
相关论文
共 33 条
  • [1] HEMODYNAMIC-RESPONSES TO DOPAMINE AND DOBUTAMINE INFUSIONS AS A FUNCTION OF DURATION OF INFUSION
    MACCANNELL, KL
    GIRAUD, GD
    HAMILTON, PL
    GROVES, G
    PHARMACOLOGY, 1983, 26 (01) : 29 - 39
  • [2] HEMODYNAMIC STEADY-STATE VIA COMBINED INFUSION OF DOBUTAMINE AND DOPAMINE IN THE PRETRANSPLANT PHASE
    PEDERSEN, JE
    MORTENSEN, SA
    ACTA CARDIOLOGICA, 1987, 42 (04) : 295 - 298
  • [3] Hemodynamic response to continuous infusion of dobutamine in Alagille's syndrome.
    Razavi, RS
    Baker, A
    Qureshi, SA
    Rosenthal, E
    Marsh, MJ
    Leech, SC
    Rela, M
    Mieli-Vergani, G
    TRANSPLANTATION, 2001, 72 (05) : 823 - 828
  • [4] PULMONARY HEMODYNAMIC-RESPONSE TO DOPAMINE AND DOBUTAMINE IN HYPEROXIC AND IN HYPOXIC DOGS
    LEJEUNE, P
    LEEMAN, M
    DELOOF, T
    NAEIJE, R
    ANESTHESIOLOGY, 1987, 66 (01) : 49 - 54
  • [5] ASSESSMENT OF VENTRICULAR-FUNCTION IN INFANTS AND CHILDREN RESPONSE TO DOBUTAMINE INFUSION
    HURWITZ, RA
    SIDDIQUI, A
    CALDWELL, RL
    WEETMAN, RM
    GIROD, DA
    CLINICAL NUCLEAR MEDICINE, 1990, 15 (08) : 556 - 559
  • [6] Randomized trial of dobutamine and dopamine in preterm infants with low systemic blood flow
    Osborn, D
    Kluckow, M
    Evans, N
    PEDIATRIC RESEARCH, 2000, 47 (04) : 422A - 422A
  • [7] EFFECT OF AN INFUSION DEVICE RATE PULSE TECHNOLOGY ON PHARMACODYNAMIC RESPONSE TO DOBUTAMINE IN INFANTS
    STOWE, CD
    PHELPS, SJ
    STORGION, SA
    LEE, KR
    CLINICAL RESEARCH, 1993, 41 (04): : A783 - A783
  • [8] INFUSION-PUMP OPERATION, FLOW-RATE, AND HEMODYNAMIC STABILITY DURING EPINEPHRINE INFUSION
    CRISP, CB
    LOVY, D
    SLATE, J
    CRITICAL CARE MEDICINE, 1994, 22 (08) : 1339 - 1340
  • [9] Randomized trial of dobutamine versus dopamine in preterm infants with low systemic blood flow
    Osborn, D
    Evans, N
    Kluckow, M
    JOURNAL OF PEDIATRICS, 2002, 140 (02): : 183 - 191
  • [10] The hemodynamic response to constant dobutamine infusion: the effect of ADRB1 389 polymorphism and sex
    Yogev, Dotan
    Basheer, Maamoun
    Perlman, Amichai
    Blotnick, Simcha
    Caraco, Yoseph
    Muszkat, Mordechai
    PHARMACOGENETICS AND GENOMICS, 2018, 28 (06): : 139 - 146